[go: up one dir, main page]

AR006915A1 - El empleo de compuestos derivados del benzofurilo, compuestos derivados del benzofurilo, procedimientos para su obtencion y un medicamento que los comprende - Google Patents

El empleo de compuestos derivados del benzofurilo, compuestos derivados del benzofurilo, procedimientos para su obtencion y un medicamento que los comprende

Info

Publication number
AR006915A1
AR006915A1 ARP970101780A ARP970101780A AR006915A1 AR 006915 A1 AR006915 A1 AR 006915A1 AR P970101780 A ARP970101780 A AR P970101780A AR P970101780 A ARP970101780 A AR P970101780A AR 006915 A1 AR006915 A1 AR 006915A1
Authority
AR
Argentina
Prior art keywords
benzofurilo
lower alkyl
derived compounds
disorders
sulfanyl
Prior art date
Application number
ARP970101780A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR006915A1 publication Critical patent/AR006915A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/86—Benzo [b] furans; Hydrogenated benzo [b] furans with an oxygen atom directly attached in position 7

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)

Abstract

Compuestos de la fórmula general (I) en donde R1-R4 significan hidrógeno, halógeno, alquilo inferior , alcoxilo inferior, arilo, benciloxilo, alcoxiloinferior, alquilo inferior-sulfanilo, alquilo inferior-sulfanilo-alquilo inferior, o R1 yR 2 juntos significan el grupo-O-(CH2)2- o -(CH2)2-O y R5significa hidrógeno o hidroxilo, así como también sus sales farmacéuticamente aceptables, en el control o prevención de enfermedades o trastornos del sistemanervioso central, tales como lamigr ana, esquizofrenia, estados de ansiedad, trastornos del sueno, anorexia, enfermedad de Alzheimer, adicciones (alcohol,nicotina, benzodiazepina, cocaína etc), así como también trastornos que resultan de lesiones en la cabeza, cerebroo en l a columna vertebral, médulaósea y respectivamente, para la elaboración de los correspondientes medicamentos.
ARP970101780A 1996-05-03 1997-04-30 El empleo de compuestos derivados del benzofurilo, compuestos derivados del benzofurilo, procedimientos para su obtencion y un medicamento que los comprende AR006915A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP96106990 1996-05-03

Publications (1)

Publication Number Publication Date
AR006915A1 true AR006915A1 (es) 1999-09-29

Family

ID=8222741

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970101780A AR006915A1 (es) 1996-05-03 1997-04-30 El empleo de compuestos derivados del benzofurilo, compuestos derivados del benzofurilo, procedimientos para su obtencion y un medicamento que los comprende

Country Status (21)

Country Link
US (1) US5955495A (es)
EP (1) EP0906301B1 (es)
JP (1) JP3148253B2 (es)
KR (1) KR100343060B1 (es)
CN (1) CN100347164C (es)
AR (1) AR006915A1 (es)
AT (1) ATE225342T1 (es)
AU (1) AU712056B2 (es)
BR (1) BR9708902A (es)
CA (1) CA2253547C (es)
CO (1) CO4940471A1 (es)
DE (1) DE69716062T2 (es)
DK (1) DK0906301T3 (es)
ES (1) ES2182070T3 (es)
HR (1) HRP970225A2 (es)
MA (1) MA24168A1 (es)
PE (1) PE64698A1 (es)
PT (1) PT906301E (es)
TR (1) TR199802206T2 (es)
WO (1) WO1997042183A1 (es)
ZA (1) ZA973708B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2786184B1 (fr) * 1998-11-24 2002-09-20 Hoechst Marion Roussel Inc Nouveaux derives du benzofurane, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant
CA2432122A1 (en) 2000-12-20 2002-08-01 Bristol-Myers Squibb Pharma Company Aryl and aminoaryl substituted serotonin receptor agonist and antagonist ligands
FR2822463B1 (fr) 2001-03-21 2004-07-30 Lipha Derives bicycliques de guanidines et leurs applications en therapeutique
AU2003216954A1 (en) * 2002-03-29 2003-10-13 Orion Corporation Treatment of dependence and dependence related withdrawal symptoms
FR2845992B1 (fr) * 2002-10-16 2005-02-04 Pf Medicament Derives de 3-(cyclopenten-1yl)-benzyl-ou3-(cyclopenten-1yl)- heteroarylmethyl-amines et leur utilisation a titre de medicaments pour le traitement de la schizophrenie
DE10257357A1 (de) 2002-12-09 2004-06-24 Bayer Ag Fluorhaltige Benzaldehyde
US7435837B2 (en) * 2003-10-24 2008-10-14 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
US20050261347A1 (en) * 2003-10-24 2005-11-24 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
US20050215644A1 (en) * 2004-03-19 2005-09-29 Interhealth Nutraceuticals, Inc. Methods for increasing neurotransmitter levels using hydroxycitric acid
EP2248524A3 (en) 2004-08-25 2011-03-09 Takeda Pharmaceutical Company Limited Preventives/remedies for stress urinary incontinence and method of screening the same
RS54876B1 (sr) 2005-05-10 2016-10-31 Incyte Holdings Corp Modulatori indoleamina 2,3-dioksigenaze i metode za upotrebu istih
ES2540561T3 (es) 2005-12-20 2015-07-10 Incyte Corporation N-hidroxiamidinoheterociclos como moduladores de indolamina 2,3-dioxigenasa
US8158617B2 (en) 2006-05-16 2012-04-17 Takeda Pharmaceutical Company Limited Fused heterocyclic compound and use thereof
CL2007002650A1 (es) 2006-09-19 2008-02-08 Incyte Corp Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
WO2008036642A2 (en) 2006-09-19 2008-03-27 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
JP5354741B2 (ja) * 2007-05-29 2013-11-27 公益財団法人大阪バイオサイエンス研究所 睡眠改善剤
EP2216023A4 (en) 2007-11-15 2013-03-13 Takeda Pharmaceutical CONDENSED PYRIDINE DERIVATIVE AND ITS USE
DK2315756T5 (en) 2008-07-08 2015-08-03 Incyte Corp 1,2,5-oxadiazoles as inhibitors of indoleamine-2,3-dioxygenase
UY32940A (es) 2009-10-27 2011-05-31 Bayer Cropscience Ag Amidas sustituidas con halogenoalquilo como insecticidas y acaricidas
JPWO2011071136A1 (ja) 2009-12-11 2013-04-22 アステラス製薬株式会社 線維筋痛症治療剤
CN104045631A (zh) * 2013-03-13 2014-09-17 无锡万全医药技术有限公司 一种制备5-(4-(4-(5-氰基-1h-吲哚-3-基)丁基)哌嗪-1-基)苯并呋喃-2-甲酰胺的新方法
CN103360374B (zh) * 2013-07-12 2016-03-09 苏州永健生物医药有限公司 维拉唑酮及其盐的合成方法
TWI651311B (zh) 2013-11-08 2019-02-21 英塞特控股公司 用於合成吲哚胺２，３－雙加氧酶抑制劑之方法
WO2019131902A1 (ja) 2017-12-27 2019-07-04 武田薬品工業株式会社 腹圧性尿失禁および便失禁の治療薬
CN114315773B (zh) * 2020-09-29 2024-01-16 广东东阳光药业股份有限公司 一种哌嗪化合物及其制备方法
WO2024206712A1 (en) * 2023-03-31 2024-10-03 Tactogen Inc. Advantageous fluorobenzofurans for the treatment of mental disorders or enhancement

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4420476A (en) 1982-05-24 1983-12-13 Averst McKenna & Harrison, Inc. Benzofuro[3,2-c]pyrazol-3-amine derivatives
DE68901424D1 (de) * 1988-07-05 1992-06-11 Akzo Nv Verbindungen mit bronchodilatatorischer aktivitaet.
US5026726A (en) * 1989-12-11 1991-06-25 The University Of New Mexico Gossylic iminolactones and gossylic lactones and their anti-viral activities

Also Published As

Publication number Publication date
CN100347164C (zh) 2007-11-07
ZA973708B (en) 1997-11-03
ATE225342T1 (de) 2002-10-15
WO1997042183A1 (en) 1997-11-13
PE64698A1 (es) 1998-10-27
HRP970225A2 (en) 1998-04-30
ES2182070T3 (es) 2003-03-01
US5955495A (en) 1999-09-21
JP3148253B2 (ja) 2001-03-19
MA24168A1 (fr) 1997-12-31
CN1217720A (zh) 1999-05-26
TR199802206T2 (xx) 2001-12-21
DK0906301T3 (da) 2003-02-10
DE69716062D1 (de) 2002-11-07
PT906301E (pt) 2003-02-28
DE69716062T2 (de) 2003-06-18
EP0906301B1 (en) 2002-10-02
EP0906301A1 (en) 1999-04-07
CA2253547A1 (en) 1997-11-13
KR20000010708A (ko) 2000-02-25
AU2769697A (en) 1997-11-26
KR100343060B1 (ko) 2002-09-18
AU712056B2 (en) 1999-10-28
BR9708902A (pt) 1999-08-03
CO4940471A1 (es) 2000-07-24
JPH11508283A (ja) 1999-07-21
CA2253547C (en) 2006-10-17

Similar Documents

Publication Publication Date Title
AR006915A1 (es) El empleo de compuestos derivados del benzofurilo, compuestos derivados del benzofurilo, procedimientos para su obtencion y un medicamento que los comprende
DE69724108T2 (de) Isochinolinderivate und arzneimittel
PT1007043E (pt) Metodo para o tratamento de doencas de armazeamento lisossomico com envolvimentode cns
ES2163071T3 (es) Sulfonamidas y su utilizacion.
MX9301847A (es) Aminas biciclicas-heterociclicas farmaceuticamente activas
ATE223399T1 (de) Quinazolin-4-on ampa antagonisten
ES2037208T3 (es) Un metodo para preparar derivados 3-aminometilicos de indano, indolina, dihidrobenzofurano y dihidrobenzotiofeno.
DE68912419D1 (de) Verwendung von Uridin zur Behandlung nervöser Störungen.
KR100397721B1 (ko) 벤조피란및치료제로서의그의용도
ATE57922T1 (de) Gegebenenfalls substituierte, 1-(2'-(bis-(phenyl)-methoxy>-aethyl)-4-(3'-(bisphenyl)-methoxy>- propyl)-piperazine, verfahren zu ihrer herstellung und diese enthaltende arzneimittel.
ES2145818T3 (es) Utilizacion de la (s)-(-)-alfa-etil-2-oxo-1-pirrolidin-acetamida para la preparacion de medicamentos destinados al tratamiento de la ansiedad.
ES537300A0 (es) Procedimiento para la preparacion de gangliosidos y sus derivados administrables por nebulizacion
ES2134709B1 (es) Utilizacion de los derivados de 1-(4-(4-aril (0 heteroaril)-1-piperazinil)-butil)-1h-azol para la preparacion de un medicamento destinado al tratamiento de los transtornos obsesivo-compulsivos, de la apnea del sueño, de las disfunciones sexuales, de la emesis y del mareo en los m
DE60318567T2 (de) Piperazinbenzothiazole als wirkstoffe in der behandlung von ischämien und krankheiten des zns-systems
ECSP972101A (es) Derivados del benzofurilo y su uso
MX2022014576A (es) Derivados de 3-((1h-pirazol-4-il)metil)-6'-(fenil)-2h-(1,2'-bipiri din)-2-ona y compuestos relacionados como antagonistas de gpr139 para usarse en un método de tratamiento, por ejemplo, contra la depresión.
ES2241973T3 (es) Nuevos derivados de n-bencilpiperazina, su procedimiento de preparacion y composiciones farmaceuticas que los contienen.
ES2102417T3 (es) 9-aminotetrahidroacridinas y compuestos relacionados, un procedimiento para su preparacion y su uso como medicamentos.
ES483287A1 (es) Un procedimiento para la preparacion de nuevas dibenzo (a,d)ciclohepten-5,10-iminas sustituidas
Wall et al. Functional and morphological aggregation in the somatosensory system of primates and its relevance for central reorganization after peripheral injury.
Hebb Wilder penfield: His legacy to neurology. The frontal lobe
MAO et al. Research advances of long noncoding RNA H19 in central nervous system diseases
AR035437A1 (es) Derivados de caloporosidos, procedimiento para su preparacion, medicamento, su utilizacion para la preparacion de medicamento y el microorganismo gloeoporus dichrous.
KAPPERS IN MEMORIAM DR. LJJ MUSKENS
BR0108007A (pt) Derivados da pirrolo-isoquinolina e tetraidropirrolo-isoquinolina e seus usos como mediadores do receptor da 5-ht7

Legal Events

Date Code Title Description
FA Abandonment or withdrawal